These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 34715852)
1. How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions. Eder P; Zielińska A; Karczewski J; Dobrowolska A; Słomski R; Souto EB J Nanobiotechnology; 2021 Oct; 19(1):346. PubMed ID: 34715852 [TBL] [Abstract][Full Text] [Related]
2. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease. Shrestha N; Xu Y; Prévost JRC; McCartney F; Brayden D; Frédérick R; Beloqui A; Préat V Acta Biomater; 2022 Mar; 140():561-572. PubMed ID: 34923097 [TBL] [Abstract][Full Text] [Related]
3. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413 [TBL] [Abstract][Full Text] [Related]
4. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926 [TBL] [Abstract][Full Text] [Related]
5. Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients. Cha JM; Park DI; Park SH; Shin JE; Kim WS; Yang SK J Korean Med Sci; 2017 Jan; 32(1):85-94. PubMed ID: 27914136 [TBL] [Abstract][Full Text] [Related]
6. Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease. Li X; Yu M; Zhu Z; Lu C; Jin M; Rao Y; Zhao Q; Lu X; Yu C Carbohydr Polym; 2021 Dec; 273():118556. PubMed ID: 34560967 [TBL] [Abstract][Full Text] [Related]
7. Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases. Voci S; Gagliardi A; Ambrosio N; Zannetti A; Cosco D Drug Discov Today; 2024 Aug; 29(8):104090. PubMed ID: 38977124 [TBL] [Abstract][Full Text] [Related]
8. Reversal of anti-drug antibodies against tumor necrosis factor inhibitors with addition of immunomodulators: A systematic review and meta-analysis. Dhindsa BS; Dhaliwal A; Mashiana HS; Saghir SM; Sayles H; Mubder M; Ohning G; Eichele D Indian J Gastroenterol; 2020 Apr; 39(2):153-160. PubMed ID: 32468382 [TBL] [Abstract][Full Text] [Related]
9. AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Bhol KC; Tracey DE; Lemos BR; Lyng GD; Erlich EC; Keane DM; Quesenberry MS; Holdorf AD; Schlehuber LD; Clark SA; Fox BS Inflamm Bowel Dis; 2013 Oct; 19(11):2273-81. PubMed ID: 23949620 [TBL] [Abstract][Full Text] [Related]
10. Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease. Nakase H Gut Liver; 2020 Jan; 14(1):7-19. PubMed ID: 30919602 [TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists. Mitoma H; Horiuchi T; Tsukamoto H; Ueda N Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553 [TBL] [Abstract][Full Text] [Related]
12. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Pouillon L; Bossuyt P; Peyrin-Biroulet L Expert Opin Biol Ther; 2016 Oct; 16(10):1277-90. PubMed ID: 27329436 [TBL] [Abstract][Full Text] [Related]
13. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Bendtzen K; Ainsworth M; Steenholdt C; Thomsen OØ; Brynskov J Scand J Gastroenterol; 2009; 44(7):774-81. PubMed ID: 19140087 [TBL] [Abstract][Full Text] [Related]
15. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Peyrin-Biroulet L Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259 [TBL] [Abstract][Full Text] [Related]
16. Update on the mechanisms of action of anti‑TNF-α antibodies and their clinical implications in inflammatory bowel disease. Eder P; Linke K; Witowski J Pol Arch Med Wewn; 2016 Sep; 126(10):772-780. PubMed ID: 27872451 [TBL] [Abstract][Full Text] [Related]
17. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases. Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293 [TBL] [Abstract][Full Text] [Related]
18. Rectal delivery of Fan Y; Wang X; Yan G; Gao H; Yang M J Mater Chem B; 2023 Dec; 11(47):11228-11234. PubMed ID: 37990919 [TBL] [Abstract][Full Text] [Related]
19. Inflammatory bowel disease and targeted oral anti-TNFα therapy. Griffiths OR; Landon J; Coxon RE; Morris K; James P; Adams R Adv Protein Chem Struct Biol; 2020; 119():157-198. PubMed ID: 31997768 [TBL] [Abstract][Full Text] [Related]
20. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Porcari S; Viola A; Orlando A; Privitera AC; Ferracane C; Cappello M; Vitello A; Siringo S; Inserra G; Magnano A; Mocciaro F; Di Mitri R; Belluardo N; Fidanza O; Garufi S; Magrì G; Bertolami C; Carroccio A; Macaluso FS; Renna S; Ventimiglia M; Alibrandi A; Cottone M; Fries W; Drugs Aging; 2020 May; 37(5):383-392. PubMed ID: 32016824 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]